It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Biogen, Cisco, IDEXX Laboratories and Waters Corporation entered into a new aggregated procurement under the Net Zero ...

Technology company Cisco is among the groups involved in six virtual power purchase agreements (VPPAs) to secure energy from ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...